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Introduction: Current sepsis guidelines recommend antimicrobial treatment (AT) within one hour after onset of
sepsis-related organ dysfunction (OD) and surgical source control within 12 hours. The objective of this study was
to explore the association between initial infection management according to sepsis treatment recommendations
and patient outcome.
Methods: In a prospective observational multi-center cohort study in 44 German ICUs, we studied 1,011 patients
with severe sepsis or septic shock regarding times to AT, source control, and adequacy of AT. Primary outcome was
28-day mortality.
Results: Median time to AT was 2.1 (IQR 0.8 – 6.0) hours and 3 hours (-0.1 – 13.7) to surgical source control. Only
370 (36.6%) patients received AT within one hour after OD in compliance with recommendation. Among 422
patients receiving surgical or interventional source control, those who received source control later than 6 hours
after onset of OD had a significantly higher 28-day mortality than patients with earlier source control (42.9% versus
26.7%, P <0.001). Time to AT was significantly longer in ICU and hospital non-survivors; no linear relationship was
found between time to AT and 28-day mortality. Regardless of timing, 28-day mortality rate was lower in patients
with adequate than non-adequate AT (30.3% versus 40.9%, P < 0.001).
Conclusions: A delay in source control beyond 6 hours may have a major impact on patient mortality. Adequate
AT is associated with improved patient outcome but compliance with guideline recommendation requires
improvement. There was only indirect evidence about the impact of timing of AT on sepsis mortality.Introduction
In the treatment of severe sepsis, timely and effective
antimicrobial therapy (AT) as well as source control is
crucial and has become a key element in the resuscitation
bundles proposed by the Surviving Sepsis Campaign (SSC)
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reproduction in any medium, provided the orcultures and applying intravenous broad-spectrum anti-
microbials within 1 hour after the onset of severe sepsis
or septic shock; the guidelines also recommend initiating
surgical source control within 12 hours [1]. Numerous
studies have shown that a delay of AT and inappropriate
initial AT in this condition is associated with poor outcome
[2-6]. One retrospective study in patients with septic shock
suggests an increase of patient mortality between 7 and
8% per hour within the first 6 hours after onset of arterial
hypotension [3]. There is also evidence that delayed surgerytd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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priate time frame remains poorly defined [10].
In numerous retrospective and before-and-after studies,
improved adherence to the sepsis bundles was associated
with improved patient outcome [4,11-14]. A meta-analysis
suggests that among the individual elements of the re-
suscitation bundle, timely and appropriately administered
antimicrobials are the most important predictors for
survival [15]. However, compliance with sepsis guideline
recommendations is poor [16]. In a Spanish multicenter
trial, only 18.4% of the studied patients received AT within
the first hour of severe sepsis or septic shock. The adminis-
tration of antimicrobials within 1 hour was independently
associated with a lower risk of hospital death [6].
Application of antimicrobials without microbiological
evidence of infection might be associated with an unfavor-
able outcome [17]. Likewise, starting AT in patients with
severe sepsis before obtaining blood cultures was among
the factors that were associated with higher hospital
mortality [4]. Compliance with the recommendation to
draw two pairs of blood cultures before AT, however, was
only in the range of 54.4 to 64.5% of patients [4,13,18].
Most of the previous studies investigating the timing
of antimicrobials and the compliance with the SSC sepsis
bundles reported only ICU mortality rates, focused mainly
on patients treated in the emergency department or in the
ICU, and did not evaluate the impact of delayed source
control on patient outcome [3,5,17,19,20]. However, many
of these patients may be admitted also from general wards
or the operating room and may require effective surgical
and other measures of source control. We therefore
extended our assessment of infection control measures
to include these patients as well. The primary aim of
our cohort study was to prospectively test the hypothesis
that a delay in AT and source control after onset of sepsis-
related organ dysfunction impacts patient outcome. In
addition, we aimed to assess compliance with recent best-




This prospective study was designed as a longitudinal
multicenter observational cohort study in 42 German hos-
pitals to determine the time to AT, surgical source control
and compliance with sepsis recommendations related to
AT in patients with suspected severe sepsis or septic shock
and its impact on 28-day, ICU, and hospital mortality. Par-
ticipation of hospitals was voluntary but was restricted to
hospitals involved in the primary care of sepsis patients
and committed to participate in a quality improvement
process. Hospitals without ICUs were excluded from
this study. Potential study centers were recruited by
regional and national research and quality improvementnetworks. The objectives of the study, inclusion and
exclusion criteria, and the documentation procedures
were discussed in several national meetings before the
start of the study. The study was designed as a pragmatic
study with a minimal case report form to allow for the
participation of hospitals without research staff. This
study served as a run-in study for a cluster-randomized
trial assessing whether a multifaceted educational program
accelerates the onset of AT and improves survival (Med-
ical Education for Sepsis Source Control and Antibiotics
MEDUSA, ClinicalTrials.gov Identifier NCT01187134).
Patients
Between December 2010 and April 2011, all consecutive
adult patients treated in the ICU for proven or suspected
infection with at least one new organ dysfunction related
to the infection were eligible for inclusion. Organ dysfunc-
tions were defined as follows: acute encephalopathy,
thrombocytopenia defined as a platelet count <100,000/μl
or a drop in platelet count >30% within 24 hours, arterial
oxygen partial pressure <10 kPa (75 mmHg) when breath-
ing room air or partial pressure of arterial oxygen/fraction
of inspired oxygen ratio <33 kPa (<250 mmHg), renal
dysfunction defined as oliguria (diuresis ≤0.5 ml/kg body
weight/hour) despite adequate fluid resuscitation or an
increase of serum creatinine more than twice the
local reference value, metabolic acidosis with a base
excess < −5 mmol/l or a serum lactate >1.5 times the local
reference value, and arterial hypotension defined as sys-
tolic arterial blood pressure <90 mmHg or mean arterial
blood pressure <70 mmHg for >1 hour despite adequate
fluid loading or vasopressor therapy at any dosage to
maintain higher blood pressures [21]. Patients who re-
ceived initial infection control measures for sepsis in
another hospital and patients who did not receive full
life-sustaining treatment were excluded. The study was
reviewed and approved by the local ethics committees,
which waived the need for informed consent because of the
observational nature of the study (see Acknowledgements).
The study was also approved by the local data protection
boards.
Data collection
Onset of severe sepsis or septic shock was defined as the
time of first infection-related organ dysfunction as docu-
mented in the patient file. Patient location at time of
onset of severe sepsis was defined as the patient location
where the first infection-related organ dysfunction was
documented. For patients who developed severe sepsis
outside the ICU, this could be the prehospital setting,
the emergency department, the hospital ward, or the
operating room. Time and type of first AT as well as pre-
existing AT were also recorded from the medical records.
Any AT prescribed up to 24 hours before the onset of
Table 1 Characteristics of participating hospitals and ICUs
(n = 44)
Hospital Data
University hospital 10 (22.7%)
Level of care
Primary care hospitals 14 (31.8%)
Secondary care hospitals 12 (27.3%)
Tertiary care hospitals 18 (40.9%)
Hospital beds 581 (416 to 1,055)
Number of ICUs 2 (1 to 4)
Inhospital biochemistry laboratory 43 (97.7%)
Inhospital microbiology department 30 (68 to 2%)
ICU beds 15 (10 to 29)
ICU patients per annum 1,200 (900 to 2,050)
Emergency department
Emergency department available 37 (84.1%)
Lactate available within 1 hour 38 (86.4%)
Broad-spectrum antibiotics available 36 (81.8%)
Prehospital emergency physician available 39 (88.6%)
Data are shown as number (percentage) for categorical data or median
(interquartile range) for continuous data.
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was considered previous AT. Perioperative antimicrobial
prophylaxis was not regarded as specific AT for sepsis.
Change of empirical AT was assessed on day 5. Initial AT
was defined as inadequate if escalation had occurred within
the first 5 days. For each patient, a blinded arbitrator
assessed whether the initial AT complied with German
guideline recommendations [22]. Source control was
defined as removal of an anatomic source of infection
either by surgery or intervention (that is, computed
tomography-guided drainage). Source control was defined
as inadequate if the technical procedure was unsuccessful.
Time to source control was obtained from the medical
record. Other factors included serum lactate and procalci-
tonin at the time of onset of severe sepsis, number of
blood culture sets taken, and ICU and hospital mortality.
Severity of disease was assessed by the Simplified Acute
Physiology Score II and the Sequential Organ Failure
Assessment score on the day of sepsis diagnosis [23,24].
Data were collected by a web-based electronic case
report form using OpenClinica® (OpenClinica, LLC,
Waltham, MA, USA). Data integrity was confirmed by
data checks within the database, resulting in queries to
the investigator where applicable. Additionally, onset of
infection-related organ dysfunction and subsequent AT
were checked for plausibility by the MEDUSA study staff
and discussed with the study center staff where applicable.
Statistical analysis
The primary endpoint was survival status at day 28 after
onset of severe sepsis. Categorical data are expressed as
absolute or relative frequencies; the chi-square or Fisher's
exact test was used for inferential statistics. Continuous
data are expressed as the median and interquartile range;
the Mann–Whitney U test was used for inferential sta-
tistics. Missing data were not replaced by calculation.
We divided patients according to the timing of antimicro-
bial treatment into the following groups: previous AT, 0
to 1 hours, 1 to 3 hours, 3 to 6 hours and >6 hours [6].
Patients were grouped by time to source control into two
groups: within 6 hours or >6 hours [25]. Odds ratios (OR)
with 95% confidence intervals (CI) for the risk of death
within 28 days depending on time to AT or time to source
control were calculated by univariate and multivariate lo-
gistic regression only in those patients were treatment was
started after onset of organ dysfunction. In patients with
sepsis, prior research has identified the initial Sequential
Organ Failure Assessment score, age, and serum lactate
[20] as confounders for the risk of death. These parame-
ters were therefore included in the multivariable logistic
regression analysis to calculate adjusted ORs. In addition,
indication for source control, escalation as well as de-
escalation of empirical AT within 5 days, presence of
community acquired infection, focus of infection, andstate of blood culture withdrawal were only included
into the final model if they were associated with 28-day
mortality at P < 0.20. Goodness of fit was assessed by the
c-statistic and the Hosmer-Lemeshow test.
Results
Participating centers and patients
Hospital and ICU characteristics of the 44 participating
centers are shown in Table 1. A total of 1,048 patients
were included during the 5-month study period. Of these,
37 patients were excluded for missing values in 28-day
mortality or time to AT, resulting in 1,011 evaluable
patients. Approximately one-half of the patients (n = 504,
49.9%) were treated for surgical reasons. Organ dysfunc-
tions on the day of study inclusion were shock (n = 632,
76.4%), lactacidosis (n = 424, 51.3%), acute renal failure
(n = 307, 37.2%) thrombocytopenia (n = 238, 28.8%), pul-
monary dysfunction (n = 492, 65.8%), and septic encephal-
opathy (n = 338, 41.2%). A total 85.1% of the patients had
more than one organ failure. Patient characteristics are
shown in Table 2. The overall 28-day mortality was 34.8%;
ICU mortality and hospital mortality were 33.0% and
41.4%, respectively. There was no association of academic
versus nonacademic hospitals or hospital size with 28-day
mortality.
Timing and adequacy of antimicrobial therapy
Three hundred and seventy (36.6%) patients received anti-
microbials within 1 hour of the onset of organ dysfunction;
Table 2 Patient characteristics
28-day survivors (n = 659) 28 day nonsurvivors (n = 352) All patients (n = 1,011) P value
Male 413 (62.7%) 221 (62.8%) 634 (62.7%) 0.972
Age (years) 68 (55 to 75) 72 (64 to 79) 69 (58 to 77) <0.001
ICU admission 0.254
Elective surgery 74 (11.2%) 42 (11.9%) 116 (11.5%)
Emergency surgery 255 (38.7%) 118 (33.5%) 373 (36.9%)
Trauma 10 (1.5%) 5 (1.4%) 15 (1.5%)
Medical 304 (46.1%) 183 (52%) 487 (48.2%)
Other 16 (2.4%) 4 (1.1%) 20 (2%)
Patient location at onset of sepsis 0.426
Emergency department 93 (14.1%) 47 (13.4%) 140 (13.9%)
ICU 366 (55.6%) 214 (60.8%) 580 (57.4%)
Operating theatre 63 (9.6%) 22 (6.2%) 85 (8.4%)
Hospital ward 80 (12.2%) 41 (11.6%) 121 (12%)
Prehospital 12 (1.8%) 4 (1.1%) 16 (1.6%)
IMC 44 (6.7%) 24 (6.8%) 68 (6.7%)
Infection 0.22
Community acquired 300 (45.5%) 143 (40.6%) 443 (43.8%)
ICU/IMC acquired 170 (25.8%) 91 (25.9%) 261 (25.8%)
Hospital acquired 189 (28.7%) 118 (33.5%) 307 (30.4%)
Source of infection (multiple responses possible)
Intra-abdominal 228 (34.7%) 138 (39.2%) 366 (36.3%) 0.167
Pneumonia 221 (33.7%) 130 (36.9%) 351 (34.9%) 0.311
Urogenital 92 (14.0%) 30 (8.5%) 122 (12.1%) 0.011
Upper airway 59 (9.0%) 24 (6.8%) 83 (8.2%) 0.228
Bones/soft tissue 47 (7.2%) 25 (7.1%) 72 (7.1%) 0.966
Other 67 (11.7%) 38 (10.7%) 105 (10.4%) 0.863
Unknown 25 (3.8%) 25 (7.1%) 50 (5%) 0.022
ICU length of stay (days) 11 (4 to 26) 7 (4 to 13) 11 (4 to 24) 0.003
Hospital length of stay (days) 32 (19 to 52) 18 (14.5 to 21.5) 32 (19 to 52) 0.011
SOFA score 9 (7 to 11) 11 (9 to 15) 10 (8 to 12) <0.001
SAPS II 45 (34 to 56) 54 (45 to 68) 48 (37 to 60) <0.001
Lactate maximum (mmol/l) 2.3 (1.3 to 3.9) 4.0 (2 to 8.1) 2.7 (1.5 to 4.9) <0.001
Procalcitonin (ng/ml) 6.3 (1.6 to 25) 7.0 (2.2 to 21.9) 6.5 (1.8 to 22.8) 0.465
Categorical data are expressed as absolute or relative frequencies (number (percentage); continuous data are expressed as median (interquartile range). SOFA
score, lactate, and procalcitonin refer to the day of sepsis onset. P value refers to differences between survivors and nonsurvivors. IMC, intermediate care unit;
SAPS, Simplified Acute Physiology Score; SOFA, Sequential Organ Failure Assessment.
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in the first hour and 184 patients (18.2%) received antimi-
crobials prior to onset of organ dysfunction. Six hundred
and forty-one (63.3%) patients received their first AT more
than 1 hour after onset of organ dysfunction (Figure 1).
Median time to AT was 2.1 (interquartile range: 0.8 to 6)
hours in all patients and 2.8 (interquartile range: 1.0 to 2.8)
hours for patients that received their AT after development
of organ dysfunction. Median times by location where
sepsis developed were 2.8 (1 to 7.2) hours in intermediatecare wards, 2.7 (1.5 to 5. 2) hours in hospital wards, 2.3
(0.6 to 7.3) hours in ICUs, 2.2 (1.4 to 3.0) hours prehospital,
2.0 (1.0 to 3.5) hours in emergency departments, and 1.1
(0.2 to 4.7) hours in operating theatres. Three hundred and
twenty-one patients were admitted to the ICU with septic
shock. Median time to AT was 2.1 (1.0 to 5.0) hours in
this subgroup. The 28-day mortality was 34.9% in the 186
patients who received AT during the first hour and 36.2%
in 641 patients when AT was given more than 1 hour
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Figure 1 Twenty-eight-day mortality according to time to
antimicrobial therapy. Numbers in the bars represent number of
patients in this group. Previous AT, patients who received antimicrobial
therapy (AT) before onset of infection-related organ dysfunction.
Table 3 Time to antimicrobial therapy and source control
according to survival
Survivors Nonsurvivors P value
Time to antimicrobial therapy (hours)
28-day survival 2.0 (0.6 to 5.6) 2.5 (1.0 to 6.6) 0.112
(n = 659) (n = 352)
ICU survival 2.0 (0.7 to 5.4) 2.8 (0.9 to 7.0) 0.023
(n = 667) (n = 329)
Hospital survival 2.0 (0.6 to 5.1) 2.8 (0.9 to 7.0) 0.020
(n = 581) (n = 329)
Time to source control (hours)
28-day survival 2.0 (−0.5 to 10.1) 5.7 (0.4 to 18.0) 0.004
(n = 286) (n = 139)
ICU survival 2.0 (−0.6 to 9.1) 6.0 (0.5 to 19.9) <0.001
(n = 286) (n = 132)
Hospital survival 2.0 (−0.5 to 9.3) 5.5 (0.4 to 18.9) 0.001
(n = 249) (n = 166)
Data are shown as median and interquartile range.
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AT within 1 hour, 28-day mortality was 32.4% compared
with 36.2% for those 641 patients receiving delayed AT
(P = 0.227). There was no linear relationship between time
to AT and 28-day mortality (Figure 1). There was also no
association between time to AT and risk of death within
28 days (OR per hour increase of time to AT: 1.0 (95% CI:
1.0 to 1.0), P = 0.482) in those 849 patients that received
their AT after the first organ dysfunction. Considering a
mean time to AT of 6.1 (± standard deviation 9.5) hours,
the data would allow one to identify an effect OR of 1.02
per hour increase with an alpha level of 0.05 and a power
of 0.8.
The 28-day mortality was lower (29.9%) in patients
who developed severe sepsis or septic shock while being
treated with antimicrobials compared with a mortality rate
of 35.9% in the patients who were treated only after
diagnosis, although the difference was not statistically
significant (P = 0.121). Time to first AT was longer for
nonsurvivors than survivors (Table 3). This difference
reached statistical significance for ICU mortality (P = 0.023)
and hospital mortality (P = 0.02) but not for 28-day mortal-
ity (P = 0.112). For 763 (75.5%) patients, the initial empir-
ical therapy complied with the German recommendations
for AT. The 28-day mortality was 34.9% in the compliant
group and 34.3% in the noncompliant group (P = 0.869).
The most frequently used empirical antimicrobial
agents were piperacillin/tazobactam or ampicillin/sulbac-
tam (26.7%), followed by imipenem/cilastatin (8.2%) and
meropenem (7.8%). Empirical AT was escalated within thefirst 5 days in 423 (41.9%) patients. Therapy was escalated
more often in patients receiving antimicrobials not in
compliance with guideline recommendations (125 of 245,
51%) than in patients treated in compliance with guide-
lines (298 of 762, 39.1%; P < 0.01). For 96 patients (9.5%),
AT was de-escalated within 5 days. The 28-day mortality
rate was 22.9% in patients with de-escalation compared
with 36.0% in patients without de-escalation (P = 0.01).
For 587 (58.1%) patients, AT was deemed adequate.
In patients with inadequate AT, the 28-day mortality
rate was significantly higher compared with adequately
treated patients (40.9% vs. 30.3%, P < 0.001; Table 4).
This increased risk was also evident when patients re-
ceived AT within the first hour: in patients receiving
AT within 1 hour, 28-day mortality was 26.9% (32/119)
when this AT was deemed adequate compared with
48.5% (32/66) for patients with inadequate AT; likewise, in
patients receiving AT later than 1 hour, 28-day mortality
was 31.2% (146/468) for adequate compared with 42.7%
(118/278) for an inadequate AT (P < 0.001). Among 588
patients not requiring surgical or interventional source
control, 101/335 (30.1%) patients with adequate AT and
112/253 (44.3%) patients with inadequate AT died within
28 days (P < 0.001).
By multivariable analysis, inadequate empirical AT
(OR (95% CI): 1.44 (1.05 to 1.99)) as well as age (OR (95%
CI): 1.04 (1.03 to 1.06)), initial Sequential Organ Failure
Assessment score (OR (95% CI): 1.18 (1.13 to 1.24)) and
maximum serum lactate levels on the day of diagnosis of
severe sepsis or septic shock (OR (95% CI): 1.09 (1.05 to
1.14)) were significantly associated with an increased risk
of death. Adjusted for these and further covariates, a delay







Age 70 (58 to 77) 69 (57 to 76.2) 0.458
Infection 0.048
Community acquired 276 (47%) 166 (39.2%)
ICU/IMC acquired 144 (24.5%) 117 (27.7%)
Hospital acquired 167 (28.4%) 140 (33.1%)
28-day mortality 178 (30.3%) 173 (40.9%) <0.001
SOFA score 9 (7 to 12) 10 (8 to 12) 0.002
ICU length of stay 8.5 (4 to 22) 14 (5 to 28) <0.001
Lactate maximum (mmol/l) 2.5 (1.5 to 4.7) 2.9 (1.6 to 5) 0.09
Procalcitonin (ng/ml) 6.3 (1.7 to 21) 6.6 (1.9 to 27.9) 0.497
Inadequacy was defined as escalation of AT within 5 days. Categorical data are
expressed as absolute and relative frequencies (number (percentage)) and are
compared by the Pearson test; continuous data are expressed as median
(interquartile range) and are compared by the Kruskal–Wallis test. SOFA score,
lactate, and procalcitonin refer to the day of sepsis onset. AT, antimicrobial
therapy; IMC, intermediate care ward; SOFA, Sequential Organ Failure
Assessment.
Table 5 Multivariate logistic regression model for the




All patients (n = 725)a
Time to antimicrobial therapy >1 hourb 0.81 (0.54 to 1.23) 0.323
Initial SOFA scorec 1.19 (1.13 to 1.26) <0.001
Aged 1.04 (1.03 o 1.06) <0.001
Maximum lactate (day 1)e 1.09 (1.04 to 1.14) <0.001
Intra-abdominal focus 1.08 (0.75 to 1.57) 0.670
Urogenital focus 0.65 (0.36 to 1.14) 0.143
Unknown focus 1.26 (0.57 to 2.78) 0.574
Community-acquired infection 0.89 (0.65 to 1.22) 0.484
Inadequate empiric antimicrobial therapy 1.44 (1.05 to 1.99) 0.026
No de-escalation of antimicrobials
within 5 days
1.17 (0.66 to 2.14) 0.597
Surgical source control required (n = 234)f
Time to antimicrobial therapy >1 hourb 0.80 (0.38 to 1.72) 0.552
Initial SOFA scorec 1.19 (1.08 to 1.31) <0.001
Aged 1.06 (1.03 to 1.08) <0.001
Maximum lactate (day 1)e 1.08 (1.00 to 1.13) 0.046
Time to source control >6 hours 2.36 (1.22 to 4.71) 0.012
Intra-abdominal focus 1.08 (0.54 to 2.18) 0.822
Urogenital focus 0.43 (0.12 to 1.34) 0.165
Unknown focusg – –
Community-acquired infection 1.08 (0.58 to 2.04) 0.800
Inadequate empiric antimicrobial therapy 1.17 (0.61 to 2.24) 0.646
No de-escalation of antimicrobials
within 5 days
0.94 (0.33 to 2.81) 0.909
No surgical source control required (n = 424)h
Time to antimicrobial therapy >1 hourb 0.69 (0.39 to 1.21) 0.189
Initial SOFA scorec 1.19 (1.11 to 1.28) <0.001
Aged 1.04 (1.02 to 1.06) <0.001
Maximum lactate (day 1)e 1.12 (1.05 to 1.20) 0.001
Intra-abdominal focus 1.72 (0.93 to 3.19) 0.083
Urogenital focus 0.95 (0.47 to 1.86) 0.875
Unknown focus 1.67 (0.70 to 3.98) 0.243
Community-acquired infection 1.03 (0.64 to 1.65) 0.904
Inadequate empiric antimicrobial therapy 1.52 (0.95 to 2.42) 0.078
No de-escalation of antimicrobials
within 5 days
2.71 (1.02 to 8.40) 0.061
Adjusted odds ratios and 95% confidence intervals (CIs) for 28-day mortality.
Only patients with initiation of antimicrobial therapy as well as source control
after development of organ dysfunction and with complete observations in all
variables are entered into this analysis. Parameters not included due to result
in the monovariate analysis: surgical or interventional source control required
(P = 0.223), status of blood culture withdrawal (P = 0.779), pulmonary focus
(P = 0.491), other focus than intra-abdominal, pulmonary, urogenital or unknown
(P = 0.691). Inadequate antimicrobial therapy was defined as escalation of empiric
antimicrobial therapy within 5 days. All models showed a good separation of the
outcome (c-statistic >0.7) and a good calibration (P> 0.05 in the Hosmer–Lemeshow
test (pHLT)). SOFA, Sequential Organ Failure Assessment. aGoodness of fit: c= 0.76,
pHLT = 0.904. bAgainst previous antimicrobial therapy and antimicrobials within
1 hour after infection-related onset of organ dysfunction. cPer point increase. dPer
year. ePer mmol/l. fGoodness of fit: c = 0.79, pHLT = 0.733. gInsufficient sample size
in this subgroup. hGoodness of fit: c = 0.77, pHLT = 0.887.
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of organ dysfunction (OR (95% CI): 0.96 (0.69 to 1.33))
was not associated with an increased 28-day mortality
(Table 5). Likewise, no association between time to AT
and outcome was seen in the subgroup of patients with-
out need for surgical or interventional source control
(Table 5).
Blood culture testing
Blood cultures were taken before AT in 649 (64.2%)
patients, and 48.8% of these cultures were positive. In
269 patients (41.4% of patients from whom blood cultures
were drawn), only one set of blood cultures was obtained.
In the 317 positive blood cultures, 187 (62.1%) showed
Gram-positive bacteria, 127 (42.2%) showed Gram-negative
bacteria, and 20 (6.6%) showed fungi; 32 (10.6%) of the
positive blood cultures revealed more than one pathogen.
Among the 317 patients with a positive blood culture,
63.3% received antimicrobials before onset of organ dys-
function and 103 (33.7%) received antimicrobials after on-
set of organ dysfunction. The 28-day mortality in these
groups was 35.9% and 31.5%, respectively (P = 0.440).
Time and adequacy to source control
Surgical (84.8%) or interventional (15.9%) source control
was performed in 422 patients: overall median time to
source control was 3 (–0.1 to 13.7) hours and 6 (2 to 20)
hours, respectively, in those patients where source con-
trol was initiated after development of organ dysfunction
(n = 314). One hundred and fifty-eight of 314 patients
(50.3%) received source control within 6 hours after onset
of infection-related organ dysfunction. The time to source
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survivors (Table 3). In 55 patients (13.3%), source control
was assessed as being inadequate. The 28-day mortality
was 65.5% in patients with inadequate source control
compared with 26.7% in patients with adequate source con-
trol (P <0.01). There was no direct relationship between
time to source control and risk of death within 28 days (OR
per hour increase of time to source control: 1.0 (95% CI: 1.
to 1.0), P = 0.725). Patients who had surgical source control
delayed for more than 6 hours had a significantly higher
28-day mortality (42.9% vs. 26.7%, P <0.001); this delay was
independently associated with an increased risk of death
(Table 5). There was neither a statistically significant inter-
action nor a collinearity between time to AT and time to
source control.
Discussion
This prospective observational trial included 1,011 eva-
luable patients with severe sepsis from a large group of
academic and nonacademic hospitals. The main finding
of this study was that surgical source control within the first
6 hours was associated with 16% lower 28-day mortality.
This finding is of interest since the SSC guidelines recently
increased the window for source control from 6 hours [25]
to 12 hours [1] after diagnosis. This decision is based on a
single study in patients with necrotizing soft tissue infec-
tion, where a delay of surgery >14 hours was associated
with an increased risk of death [7]. However, this study by
Boyer and colleagues did not examine the effect of shorter
delays on mortality. While current data suggest that
delayed surgery adversely affects outcome [26,27], studies
to allow the determination of an optimal time point of
surgical source control are rare. A retrospective analysis of
patients with fecal peritonitis did not confirm a relation-
ship between duration until source control and mortality
[28]. However, overall mortality in this study was very low
with 19.1% and only 24-hour time intervals were reported.
Our data are more consistent with an observational study
of children reporting that all patients who received surgical
debridement for necrotizing fasciitis at later than 3 hours
died [8]. Likewise, a study in patients with perforated peptic
ulcers found that each hour delay in surgical source control
increases 30-day mortality by 2% [9]. Clearly, more data on
the relationship between time to source control and patient
outcome are needed. In the interim, surgical source control
should be performed as soon as possible.
Our observation that early AT of the underlying infection
of sepsis before onset of organ dysfunction is associated
with a trend towards lower 28-day mortality in the range
of 6% supports the importance of early recognition and
antimicrobial treatment of infection underlying sepsis [1].
The finding that the median time to antimicrobial treat-
ment was about 40 minutes shorter in survivors than in
nonsurvivors confirms other studies [18,29]. Median timesto antimicrobial administration were 2.1 hours after diag-
nosis of severe sepsis or septic shock and thus exceeded
guideline recommendations [1]. Similar delays have been
reported in other studies [5,13,18,20,30,31]. In contrast to
our data, a number of studies demonstrated an association
between patient outcome and time to AT in patients with
severe infections [2,32-35]. Like other studies [6,20], we
could not confirm the data of Kumar and coworkers in
patients with septic shock that suggested an increase of
7.6% in hospital mortality per hour delay in AT [3]. This
may be related to differences in the patient population or
study methodology. Kumar and colleagues focused their
work on patients with septic shock and observed a median
time to AT of 6 hours – three times longer than what we
and other studies have observed [3].
There are some other considerations that may explain
the different findings about time to AT and its association
with mortality. Firstly, some studies used the time until
adequate AT [3,5,34] rather than time to first AT, as we
did. We rather applied an approach similar to Puskarich
and colleagues because it seems unreasonable to assess
the quality of primary care with microbiological data that
are not available for the treating physician at that time
[20]; other studies also used this design [2,17,36]. Further-
more, the underlying pathogen may remain unknown and
alternative definitions of adequacy such as guideline ad-
herence [3,34] need to replace the microbiological defin-
ition of adequacy anyhow. Secondly, the definition of the
starting time for the duration until AT is defined signifi-
cantly different across the available studies and includes
hospital [33,35] or ICU admission [2], onset of arterial
hypotension [3,34], and the time when cultures were
obtained [17,36]. We have chosen onset of infection-related
organ dysfunction since this is a clinical feature that should
trigger initiation of primary sepsis care. All of the chosen
starting times may overlook that significant organ dysfunc-
tion occurred before the defined time. These considerations
suggest that the investigation of the impact of timing of
AT on patient outcome is limited in observational studies.
The concept of early empirical AT has recently been
challenged. Puskarich and colleagues did not find an
increase in mortality with each hour delay in AT in
emergency department patients with septic shock [20].
In a before-and-after-study in critically ill surgical patients,
AT initiated only after microbiological confirmation was
associated with a lower mortality rate than early empirical
AT [17]. However, the overall long delays to antimicrobial
administration in both groups (11 and 17.7 hours, respect-
ively) limit interpretation of results from that study [37].
In general, compliance with sepsis guideline recommen-
dations was poor. Only one-third of patients received their
first antimicrobial agent according to current guideline
recommendations before or within 1 hour of diagnosis
of severe sepsis. Blood cultures before AT were taken in
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were obtained in only one-half of these patients. Choice of
antimicrobials complied with German recommendations
for empirical AT [22] in 75% of cases. Nevertheless, in
about 40% of patients the treating physicians considered
first AT as inadequate and escalated AT within the first
5 days. Overall, 28-day mortality of these patients was
considerably increased. The association between adequacy
of AT and patient outcome remained significant regardless
of whether AT was given earlier or later than 1 hour after
onset of severe sepsis. This was also true for the 588 pa-
tients not requiring surgical or interventional source con-
trol. Therefore it seems unlikely that AT was deemed
inadequate and changed because the patient deteriorated
for reasons unrelated to the microbiological inappropriate-
ness of AT, such as inadequate surgical source control. In-
creased mortality in patients with inappropriate initial AT
has also been observed in other studies [38,39]. Recent data
from the EUROBACT study concluded that infections
with multiresistant organisms are associated with a delay
of appropriate AT and increased mortality [40].
Current guidelines recommend at least two sets of
blood cultures before starting AT [1]. In our study, two-
thirds of patients had blood cultures drawn before AT.
However, only one set was drawn in about 50% of those
patients. Drawing blood cultures before initiation of
broad-spectrum antimicrobials was associated with a
lower risk of death in the SSC database [4] but not in
our study. This may be explained by the much larger
sample size in the SSC database.
Our study has strengths and weaknesses. Strengths
include the prospective data collection and multicenter
design. Unlike previous studies, our study used short-term
prospective data collection and is therefore not influenced
by secular trends. Furthermore, reporting of times to AT
not only in the ICU but also in other locations as well as
outside the hospital and inclusion of medical centers with
all levels of care increases the generalizability of our results.
Although we enrolled over 1,000 patients, the sample size
may not have been large enough to detect small differences
in outcome; moreover, we cannot rule out that eligible
patients were not included in the study because of limited
resources. We also did not include patients who were not
referred to the ICU. However, it is unlikely that many such
patients were missed since in Germany the majority of pa-
tients with organ dysfunction are referred to an ICU or
intermediate care unit.
We did not assess adequacy of AT by means of micro-
biological susceptibility testing results because many of
the included hospitals lacked the staff to report such data
for a study. Instead, we used the pragmatic approach to
ask physicians to record any change of AT within 5 days,
which was defined a priori as an indication of inad-
equate initial therapy. Despite the fact that we foundthis association also in nonsurgical patients, we cannot
rule out that AT was changed because the patient deterio-
rated for reasons that were not related to the microbio-
logical inappropriateness of AT. Except for serum lactate
measurements, which were obtained in 95.2% of the pa-
tients at baseline, we did not assess the compliance with
other guideline recommendations and therefore cannot
rule out that mortality rates were potentially influenced by
unmeasured effects; for instance, timely fluid resuscitation
or appropriate use of other supportive measures.
Conclusions
More data on the relationship between time to source
control and patient outcome are needed. In the interim,
surgical source control should be performed as soon as
possible. Adequacy of empirical AT is important for the
survival in sepsis, and choice of initial AT is an important
decision in the therapy of these patients. There was only
indirect evidence about the impact of timing of AT on
sepsis mortality but evidence about this issue varies
significantly among the available studies. Randomized
controlled trials are thus necessary to further elucidate
the impact of AT timing on survival. Quality improvement
initiatives should not be restricted to severe sepsis but
should also focus on the timely recognition and adequate
treatment of infections to prevent their progress to severe
sepsis.
Key messages
 A delay of surgical or interventional source control
of more than 6 hours was associated with increased
mortality.
 Although survivors had a shorter time to AT than
nonsurvivors, there was no significant association or
linear relationship between time to AT and survival.
 An inadequate empiric AT was associated with an
increased mortality.
 Compliance with guidelines regarding anti-infectious
measures regarding timing and choice of empiric
AT, withdrawal of blood cultures, and de-escalation
of AT should be improved.
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